PURPOSE: To investigate the diagnostic performance of circulating tumor cells (CTC) in discrimination between primary lung cancer and nonmalignant diseases as well as in prediction of distant metastasis. PATIENTS AND METHODS: We prospectively evaluated CTCs in 7.5-mL samples of peripheral blood sampled from patients with a suspicion or a diagnosis of primary lung cancer. A semiautomated system was used to capture CTCs with an antibody against epithelial cell adhesion molecule. RESULTS: Of 150 eligible patients, 25 were finally diagnosed as having nonmalignant disease, and 125 were diagnosed as having primary lung cancer with (n = 31) or without (n = 94) distant metastasis. CTCs were detected in 30.6% of lung cancer patients and in 12.0% of nonmalignant patients. CTC count was significantly higher in lung cancer patients than in nonmalignant patients, but a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between lung cancer and nonmalignant diseases with an area under ROC curve of 0.598 (95% confidence interval, 0.488-0.708; P = 0.122). Among lung cancer patients, CTC count significantly increased along with tumor progression, especially with development of distant metastasis. The area under ROC curve for CTC count in prediction of distant metastasis was 0.783 (95% confidence interval, 0.679-0.886; P < 0.001). When patients with one or more CTCs were judged as having metastatic disease, sensitivity and specificity of the CTC test were 71.0% and 83.0%, respectively. CONCLUSIONS: CTC is a useful surrogate marker of distant metastasis in primary lung cancer.
PURPOSE: To investigate the diagnostic performance of circulating tumor cells (CTC) in discrimination between primary lung cancer and nonmalignant diseases as well as in prediction of distant metastasis. PATIENTS AND METHODS: We prospectively evaluated CTCs in 7.5-mL samples of peripheral blood sampled from patients with a suspicion or a diagnosis of primary lung cancer. A semiautomated system was used to capture CTCs with an antibody against epithelial cell adhesion molecule. RESULTS: Of 150 eligible patients, 25 were finally diagnosed as having nonmalignant disease, and 125 were diagnosed as having primary lung cancer with (n = 31) or without (n = 94) distant metastasis. CTCs were detected in 30.6% of lung cancerpatients and in 12.0% of nonmalignant patients. CTC count was significantly higher in lung cancerpatients than in nonmalignant patients, but a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between lung cancer and nonmalignant diseases with an area under ROC curve of 0.598 (95% confidence interval, 0.488-0.708; P = 0.122). Among lung cancerpatients, CTC count significantly increased along with tumor progression, especially with development of distant metastasis. The area under ROC curve for CTC count in prediction of distant metastasis was 0.783 (95% confidence interval, 0.679-0.886; P < 0.001). When patients with one or more CTCs were judged as having metastatic disease, sensitivity and specificity of the CTC test were 71.0% and 83.0%, respectively. CONCLUSIONS: CTC is a useful surrogate marker of distant metastasis in primary lung cancer.
Authors: Anders Carlsson; Viswam S Nair; Madelyn S Luttgen; Khun Visith Keu; George Horng; Minal Vasanawala; Anand Kolatkar; Mehran Jamali; Andrei H Iagaru; Ware Kuschner; Billy W Loo; Joseph B Shrager; Kelly Bethel; Carl K Hoh; Lyudmila Bazhenova; Jorge Nieva; Peter Kuhn; Sanjiv S Gambhir Journal: J Thorac Oncol Date: 2014-08 Impact factor: 15.609
Authors: Ja Hye Myung; Monic Roengvoraphoj; Kevin A Tam; Tian Ma; Vincent A Memoli; Ethan Dmitrovsky; Sarah J Freemantle; Seungpyo Hong Journal: Anal Chem Date: 2015-09-10 Impact factor: 6.986
Authors: Elizabeth A Punnoose; Siminder K Atwal; Jill M Spoerke; Heidi Savage; Ajay Pandita; Ru-Fang Yeh; Andrea Pirzkall; Bernard M Fine; Lukas C Amler; Daniel S Chen; Mark R Lackner Journal: PLoS One Date: 2010-09-08 Impact factor: 3.240